Nautilus Biotechnology, Inc.

Listed Company

NAUTCIK 0001808805NasdaqNon-AcceleratedSmaller ReportingLaboratory Analytical InstrumentsFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-59.00M

Total Assets

$191.11M

Equity

$156.97M

Shares Out

127.08M

Op. Cash Flow

$-50.70M

Business

Nautilus Biotechnology, Inc. is a development-stage life sciences company creating a platform technology to quantify and unlock the complexity of the proteome using single‑protein molecule analysis. It offers an end-to-end Nautilus platform comprising a proteome analysis system instrument, reagent consumables (flow cells, sample preparation kits and affinity reagent probes), and cloud-based machine learning analysis software delivered as a SaaS. Key business activities center on product development, research collaborations, early access services and direct commercialization of instruments and consumables. The company targets life sciences research customers via direct sales, research partnerships and early access programs in the United States with planned expansion into Europe and Asia Pacific.

Summary from filing dated 2025-02-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	41	50	47	38	29
General and administrative	26	31	29	26	21
Total operating expenses	67	81	76	64	50
Interest income	8	11	13	6	329,000
Other expense	−32,000	−84,000	−73,000	−122,000	−146,000
Total other income	8	11	12	6	183,000
Net loss	−59	−71	−64	−58	−50
Net loss per share attributable to common stockholders, basic (in dollars per share)	−0.47	−0.56	−0.51	−0.46	−0.6
Net loss per share attributable to common stockholders, diluted (in dollars per share)	−0.47	−0.56	−0.51	−0.46	−0.6
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares)	126	125	125	125	84
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares)	126	125	125	125	84

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	12	28	19	115	186
Short-term investments	91	102	154	70	160
Prepaid expenses and other current assets	3	3	3	3	3
Total current assets	106	133	177	187	349
Property and equipment, net	3	4	4	4	2
Operating lease right-of-use assets	28	28	33	29	29
Long-term investments	53	76	91	129	—
Other long-term assets	1	1	1	1	997,000
Total assets	191	243	306	350	398
Accounts payable	943,000	987,000	2	1	2
Accrued expenses and other liabilities	3	3	4	4	3
Current portion of operating lease liability	4	4	4	2	970,000
Total current liabilities	8	8	9	7	6
Operating lease liability, net of current portion	26	26	31	28	29
Total liabilities	34	34	40	35	35
Commitments and contingencies (Note 8)	—	—	—	—	—
Preferred stock, $0.0001 par value, 200,000,000 authorized as of December 31, 2025 and 2024, respectively; 0 shares issued and outstanding as of December 31, 2025 and 2024, respectively	0	0	0	0	0
Common stock, $0.0001 par value, 1,000,000,000 shares authorized as of December 31, 2025 and 2024, respectively; 126,469,610 and 126,106,176 shares issued and outstanding as of December 31, 2025 and 2024, respectively	13,000	13,000	13,000	12,000	12,000
Additional paid-in capital	489	482	468	455	444
Accumulated other comprehensive income	243,000	57,000	−255,000	−2	−184,000
Accumulated deficit	−332	−273	−202	−139	−81
Total stockholders equity	157	209	265	315	364
Total liabilities and stockholders equity	191	243	306	350	398

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Stock-based compensation	7	13	12	10	8
Amortization of operating lease right-of-use assets	5	4	4	2	2
Depreciation	2	2	—	—	—
In-process research and development	0	760,000	0	—	—
Amortization (accretion) of premiums (discounts) on securities, net	−1	−3	−3	−890,000	183,000
Prepaid expenses and other assets	544,000	666,000	−821,000	756,000	−3
Accounts payable	−69,000	−578,000	393,000	−561,000	1
Accrued expenses and other liabilities	629,000	−1	417,000	409,000	2
Operating lease liabilities	−5	−4	−3	−1	−788,000
Net cash used in operating activities	−51	−59	−52	−46	−39
Proceeds from maturities of securities	109	155	72	163	85
Purchases of securities	−72	−86	−113	−187	−222
Purchases of property and equipment	−1	−2	−2	−2	−2
Cash paid in connection with asset acquisition	0	−760,000	0	—	—
Net cash provided by investing activities	35	66	−44	−26	−139
Proceeds from exercise of stock options	58,000	620,000	104,000	330,000	167,000
Proceeds from issuance of common stock under employee stock purchase plan	156,000	524,000	264,000	232,000	0
Net cash provided by financing activities	214,000	1	368,000	562,000	327
Net increase (decrease) in cash, cash equivalents and restricted cash	−15	8	−95	−71	149
Acquisitions of property and equipment included in accounts payable	99,000	74,000	148,000	174,000	64,000
Remeasurement of lease liabilities and right-of-use assets	4	0	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro